Skip Navigation

Treatment of Recurrent Adult Acute Lymphoblastic Leukemia

For information about the treatments listed below, see the Treatment Option Overview section.

Standard treatment of recurrent adult acute lymphoblastic leukemia (ALL) may include the following:

  • Combination chemotherapy followed by stem cell transplant.
  • Monoclonal antibody therapy (blinatumomab or inotuzumab ozogamicin) followed by stem cell transplant.
  • Low-dose radiation therapy as palliative care to relieve symptoms and improve the quality of life.
  • Tyrosine kinase inhibitor therapy with dasatinib for certain patients.

Some of the treatments being studied in clinical trials for recurrent adult ALL include the following:

  • A clinical trial of stem cell transplant using the patient's stem cells.
  • A clinical trial of targeted therapy.
  • A clinical trial of CAR T-cell therapy.
  • A clinical trial of new anticancer drugs.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

This information is not intended to replace the advice of a doctor. Navigating Care disclaims any liability for the decisions you make based on this information. This information was sourced and adapted from Adapted from the National Cancer Institute's Physician Data Query (PDQ®) Cancer Information Summaries on www.cancer.gov.

See Expert Resources

The Navigating Care Library includes articles about cancer, chemotherapy regimens and drugs from the the National Cancer Institute and other experts.